| Identification | Back Directory | [Name]
Infliximab | [CAS]
170277-31-3 | [Synonyms]
Avakine
CT-P 13
Remicade
Unii-B72hh48flu
Infliximab USP/EP/BP
Immunoglobulin G, anti-(human tumor necrosis factor) (human-mouse monoclonal ca2 heavy chain), disulfide with human-mouse monoclonal ca2 light chain, dimer | [MDL Number]
MFCD06795259 |
| Hazard Information | Back Directory | [Uses]
Infliximab targets the transcription factor NF-κB with harmine and related compounds for treatment of cancers and inflammatory diseases and combination with other agents | [in vivo]
A single injection of Infliximab (10 μg/g in 100 μL saline/dose ip) in diabetic TNF-α+/+) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root ganglion is also attenuated by Infliximab[2]. | [storage]
Store at -30°C |
|
|